How I Treat ALK+ NSCLC With ALK TKis in 2021: Alectinib, Crizotinib, Ceritinib, Brigatinib, Ensartinib & Lorlatinib Efficacy Comparison, Acquired Resistance

Dr. Joshua Reuss from Georgetown University talks about how he treats ALK+ lung cancer patients with current available treatments. SEE VIDEO

VuMedi

Author: Joshua Reuss